<DOC>
	<DOCNO>NCT00001965</DOCNO>
	<brief_summary>This study examine effectiveness drug cyclosporine treat hypertrophic cardiomyopathy ( HCM ) , condition heart muscle thickens . The thickened muscle impair heart 's pump action decrease blood supply , . Various symptom , chest pain , shortness breath , fatigue , palpitation , may result . In animal study , cyclosporine prevent heart muscle thicken mouse engineer develop thick heart . Patients HCM 18 75 year old screen study protocol 98-H-0102 protocol . Screening test include blood test , echocardiogram measure heart thickness , Holter monitor record heartbeat , treadmill exercise test , various image test include thallium scan , radionuclide angiography , magnetic resonance imaging ( MRI ) , cardiac catheterization examine heart function blood supply . Patients admit study randomly assign take either cyclosporine tablet placebo ( look-alike tablet active ingredient ) twice day 6 month . During brief hospital stay start study , blood sample take measure cyclosporine level . After discharge , heart rate blood pressure check blood test do follow-up visit week 2 week every two week end 6-month treatment period . At time , patient hospitalize second time repeat test determine effect drug heart condition . They include thallium scan , radionuclide angiogram , MRI , treadmill exercise test , cardiac catheterization , echocardiogram . An echocardiogram MRI repeat 1 year start study evaluate long term effect drug , .</brief_summary>
	<brief_title>Cyclosporine A Treat Hypertrophic Cardiomyopathy ( HCM )</brief_title>
	<detailed_description>Hypertrophic cardiomyopathy ( HCM ) genetic cardiac disease characterize marked increase cardiac mass cause proliferation/hypertrophy several cell type ( myocytes , fibroblast , smooth muscle cell , endothelial cell ) . There often associate leave ventricular ( LV ) diastolic dysfunction myocardial ischemia . The severity LV hypertrophy , diastolic dysfunction , myocardial ischemia important determinant clinical course . In several animal model LV hypertrophy , calcineurin implicate development myocardial hypertrophy , lead cardiac dilatation failure . Inhibitors calcineurin ( Cyclosporin A FK506 ) show prevent development cardiac hypertrophy animal model , cardiac hypertrophy relate sarcomeric dysfunction . We propose study ability Cyclosporin A ( CsA ) reduce LV mass , improve symptom , LV diastolic function , myocardial perfusion HCM cause sarcomeric gene mutation .</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Cardiomyopathy , Hypertrophic</mesh_term>
	<mesh_term>Cardiomegaly</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>Patients either gender , age 1875 year , HCM cause sarcomeric gene mutation determine exist protocol . LV wall thickness great equal 20 mm measure LV segment MRI . Severe symptoms refractory medical treatment ( New York Heart Association functional class III IV ) . No LV outflow tract obstruction rest great 30 mm Hg determine cardiac catheterization . No coronary artery disease ( great 50 % arterial luminal narrowing major epicardial vessel ) . No chronic atrial fibrillation . No bleed disorder ( PTT great 35 sec , pro time great 14 sec , platelet count le 154 k/mm ( 3 ) . No anemia ( Hb le 12.7 g/dl male less 11.0 g/dl female ) . No renal impairment ( serum creatinine great 1.3 mg/dl ) . No hepatitis B C ; unexplained abnormal LFTs . No inability estimate LV wall thickness . No positive urine pregnancy test . No pregnant lactate female patient . No concurrent use immunosuppressives steroid . No diabetes mellitus . No history malignancy skin tumor ( squamous basal cell ) last 5 year . No condition exclude patient undergo MRI test .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 1999</verification_date>
	<keyword>Calcineurin</keyword>
	<keyword>Cardiac Hypertrophy</keyword>
	<keyword>Hypertrophic Cardiomyopathy</keyword>
</DOC>